Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K(ATP) Channel

PURPOSE: Romidepsin is a histone deacetylase inhibitor (HDI) approved for the treatment of both cutaneous and peripheral T-cell lymphoma (CTCL and PTCL). During development, a thorough assessment of cardiac toxicity was conducted. EXPERIMENTAL DESIGN: A phase II single-agent nonrandomized study of r...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Noonan, Anne M., Eisch, Robin A., Liewehr, David J., Sissung, Tristan M., Venzon, David J., Flagg, Thomas P., Haigney, Mark C., Steinberg, Seth M., Figg, William D., Piekarz, Richard L., Bates, Susan E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448401/
https://ncbi.nlm.nih.gov/pubmed/23589175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0109
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg